Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics, a leader in clinical genomic ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...

Biocomputing is transitioning to deployment, shifting from research to real-world use in healthcare and industrial biotechnology. Key opportunities include DNA and RNA computing for data storage and ...

Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the ...

New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predisposition. PALB2 is one of the ...

Ambry Genetics launched RNA testing commercially in 2019 as +RNAinsight. Data from over 450,000 patients showed that 1 in 25 positive patients would have been missed without RNA data. The data also ...

Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new research leveraging Multiplexed Assays ...

The famous investor Cathie Wood is renowned for choosing companies focused on disruptive innovation, meaning companies that ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...